Coherus swings to FY 2024 net income of $28.5M; UDENYCA divestiture on track

Coherus Oncology, Inc.

FY 2024 net income $28.5M ($0.25 diluted EPS) vs net loss $237.9M in FY 2023; revenue $267M, +4%.
UDENYCA net revenue $206M (+62% YoY); LOQTORZI Q4 revenue $7.5M, +29% QoQ.
Non-GAAP net loss $86.3M ($0.75 loss per share) improved from $186.2M in FY 2023.
UDENYCA divestiture up to $558.4M; shareholder vote March 11, expected close late Q1/early Q2 2025.
Post-divestiture projected cash ~$250M, cash runway >2 years; headcount reduction ~30%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.